HEADER BLOOD CLOTTING 13-SEP-02 1MQ6 TITLE CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) TITLE 2 AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL) TITLE 3 METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN TITLE 4 FACTOR XA COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR X HEAVY CHAIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: CATALYTIC DOMAIN; COMPND 5 SYNONYM: STUART FACTOR; COMPND 6 EC: 3.4.21.6; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: COAGULATION FACTOR X LIGHT CHAIN; COMPND 9 CHAIN: L; COMPND 10 FRAGMENT: EPIDERMAL GROWTH FACTOR LIKE DOMAIN 2; COMPND 11 SYNONYM: STUART FACTOR; COMPND 12 EC: 3.4.21.6 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 OTHER_DETAILS: EXTRACTED FROM BLOOD; SOURCE 6 MOL_ID: 2; SOURCE 7 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 8 ORGANISM_COMMON: HUMAN; SOURCE 9 ORGANISM_TAXID: 9606; SOURCE 10 OTHER_DETAILS: EXTRACTED FROM BLOOD KEYWDS PROTEIN INHIBITOR COMPLEX, COAGULATION COFACTOR, PROTEASE, BLOOD KEYWDS 2 CLOTTING EXPDTA X-RAY DIFFRACTION AUTHOR M.ADLER,M.WHITLOW REVDAT 5 30-OCT-24 1MQ6 1 REMARK LINK REVDAT 4 11-OCT-17 1MQ6 1 REMARK REVDAT 3 13-JUL-11 1MQ6 1 VERSN REVDAT 2 24-FEB-09 1MQ6 1 VERSN REVDAT 1 28-JAN-03 1MQ6 0 JRNL AUTH M.ADLER,M.J.KOCHANNY,Y.BIN,G.RUMENNIK,D.L.LIGHT, JRNL AUTH 2 S.BIANCALANA,M.WHITLOW JRNL TITL CRYSTAL STRUCTURES OF TWO POTENT NONAMIDINE INHIBITORS BOUND JRNL TITL 2 TO FACTOR XA JRNL REF BIOCHEMISTRY V. 41 15514 2002 JRNL REFN ISSN 0006-2960 JRNL PMID 12501180 JRNL DOI 10.1021/BI0264061 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.ADLER,D.D.DAVEY,G.B.PHILLIPS,S.H.KIM,J.JANCARIK, REMARK 1 AUTH 2 G.RUMENNIK,D.L.LIGHT,M.WHITLOW REMARK 1 TITL PREPARATION, CHARACTERIZATION AND THE CRYSTAL STRUCTURE OF REMARK 1 TITL 2 THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA REMARK 1 REF BIOCHEMISTRY V. 39 12534 2000 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI001477Q REMARK 1 REFERENCE 2 REMARK 1 AUTH S.MAIGNAN,J.P.GUILLOTEAU,S.POUZIEUX,Y.M.CHOI-SLEDESKI, REMARK 1 AUTH 2 M.R.BECKER,S.I.KLEIN,W.R.EWING,H.W.PAULS,A.P.SPADA,V.MIKOL REMARK 1 TITL CRYSTAL STRUCTURES OF HUMAN FACTOR XA COMPLEXED WITH POTENT REMARK 1 TITL 2 INHIBITORS REMARK 1 REF J.MED.CHEM. V. 43 3226 2000 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM000940U REMARK 1 REFERENCE 3 REMARK 1 AUTH G.B.PHILLIPS,B.O.BUCKMAN,D.D.DAVEY,K.A.EAGEN,W.J.GUILFORD, REMARK 1 AUTH 2 J.HINCHMAN,E.HO,S.KOOVAKKAT,A.M.LIANG,D.R.LIGHT,R.MOHAN, REMARK 1 AUTH 3 H.P.NG,J.M.POST,K.J.SHAW,D.SMITH,B.SUBRAMANYAM,M.E.SULLIVAN, REMARK 1 AUTH 4 L.TRINH,R.VERGONA,J.WALTERS,K.WHITE,M.WHITLOW,S.WU,W.XU, REMARK 1 AUTH 5 M.M.MORRISSEY REMARK 1 TITL DISCOVERY OF REMARK 1 TITL 2 N-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-3,5-DIFLUORO- REMARK 1 TITL 3 6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL) REMARK 1 TITL 4 PHENOXY]PYRIDIN-4-YL]-N-METHYLGLYCINE (ZK-807834): A POTENT, REMARK 1 TITL 5 SELECTIVE, AND ORALLY ACTIVE INHIBITOR OF THE BLOOD REMARK 1 TITL 6 COAGULATION ENZYME FACTOR XA REMARK 1 REF J.MED.CHEM. V. 41 3557 1998 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM980280H REMARK 2 REMARK 2 RESOLUTION. 2.10 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.10 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 2.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 17183 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.186 REMARK 3 FREE R VALUE : 0.268 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.000 REMARK 3 FREE R VALUE TEST SET COUNT : 643 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.10 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.19 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1276 REMARK 3 BIN R VALUE (WORKING SET) : 0.2932 REMARK 3 BIN FREE R VALUE : 0.3366 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 55 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2220 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 55 REMARK 3 SOLVENT ATOMS : 164 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 56.09 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 36.34 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.94990 REMARK 3 B22 (A**2) : 8.68510 REMARK 3 B33 (A**2) : -5.73510 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.011 REMARK 3 BOND ANGLES (DEGREES) : 2.010 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : 1.590 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; 2.500 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO,PARAM11.WAT REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: FINAL REFINEMENT HAD A B FACTOR REMARK 3 OPTIMIZATION AND A FINAL POWELL MINIMIZATION. REMARK 4 REMARK 4 1MQ6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 24-SEP-02. REMARK 100 THE DEPOSITION ID IS D_1000017091. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 30-MAY-00 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.50 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.033 REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : X-GEN REMARK 200 DATA SCALING SOFTWARE : X-GEN REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 19603 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.100 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 3.540 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.06730 REMARK 200 FOR THE DATA SET : 8.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.10 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.50 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.36130 REMARK 200 FOR SHELL : 1.300 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: DIRECT REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: PDB ENTRY 1FJS REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.44 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: A THREE-FOLD EXCESS OF A PROPRIETARY REMARK 280 FACTOR XA INHIBITOR WITH PICOMOLAR AFFINITY WAS ADDED TO THE DES- REMARK 280 GLA-FACTOR XA. THIS INHIBITOR IS BASED ON THE SAME TEMPLATE AS REMARK 280 XLD IN 1MQ6. THE PROTEIN WAS THEN CONCENTRATED TO 12-17 MG/ML. REMARK 280 CRYSTALS WERE GROWN USING 2 UL OF COMPLEX WITH 2 UL OF RESERVOIR REMARK 280 CONTAINING 15-21% PEG1500 AND 10 MM CACL2. 30-40 UL SITTING REMARK 280 DROPS CONTAINING SATURATED INHIBITOR (5 MM) IN 21% PEG1500, 5 MM REMARK 280 CACL2, 20 MM NACL, 25 MM TRIS PH 7.5 (CRYSTAL SOAKING SOLUTION) REMARK 280 WERE EQUILIBRATED OVER A 1 ML RESERVOIR CONTAINING THE CRYSTAL REMARK 280 SOAKING SOLUTION FOR 1 TO 2 DAYS. A SINGLE FACTOR XA CRYSTAL WAS REMARK 280 TRANSFERRED USING A MOUNTED CRYOLOOP INTO ONE OF THESE SITTING REMARK 280 DROPS AND ALLOWED TO SOAK FOR THREE OR MORE DAYS. AFTER THE REMARK 280 INITIAL SOAK, EACH CRYSTAL WAS THEN TRANSFERRED TO AN UNUSED REMARK 280 DROP AND ALLOWED TO SOAK FOR SECOND PERIOD OF THREE OR MORE REMARK 280 DAYS. PH 7.50, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 28.32000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 39.51000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 36.64500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 39.51000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.32000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 36.64500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 THIS ENTRY CONTAINS THE CRYSTALLOGRAPHIC REMARK 300 ASYMMETRIC UNIT WHICH CONSISTS OF 2 CHAIN(S). REMARK 300 FACTOR XA FORMS A COMPLEX WITH FACTOR VA IN REMARK 300 THE PRESENCE OF CALCIUM AND A PHOSPHOLIPID REMARK 300 MEMBRANE TO PRODUCE THE PROTHROMBINASE COMPLEX. REMARK 300 THIS ENTRY CONTAINS THE EPIDERMAL GROWTH FACTOR REMARK 300 LIKE DOMAIN 2(L) AND THE CATALYTIC DOMAIN (A) REMARK 300 OF FACTOR XA IN THE CRYSTALLOGRAPHIC ASYMMETRIC REMARK 300 UNIT. THE COORDINATES DO NOT CONTAIN THE GLA REMARK 300 DOMAIN OR THE EPIDERMAL GROWTH FACTOR LIKE DOMAIN REMARK 300 1 OF FACTOR XA. ALTHOUGH THE ASYMMETRIC UNIT REMARK 300 CONTAINS A FUNCTIONAL PROTEASE, IT DOES HAVE THE REMARK 300 SAME SPECIFICITY AS THE PROTHROMBINASE COMPLEX. REMARK 300 SEE REMARK 350 FOR INFORMATION ON GENERATING THE REMARK 300 BIOLOGICAL MOLECULE(S). REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3630 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12690 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -43.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, L REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU A 37 CG CD OE1 OE2 REMARK 480 LYS A 62 CG CD CE NZ REMARK 480 ARG A 63 CB CG CD NE CZ NH1 NH2 REMARK 480 LYS A 223 CG CD CE NZ REMARK 480 LYS A 236 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 74 65.36 -115.08 REMARK 500 GLN A 75 129.53 174.39 REMARK 500 ARG A 115 -177.31 -174.96 REMARK 500 ALA A 221 14.95 59.30 REMARK 500 LEU L 88 -116.12 48.93 REMARK 500 ASN L 93 23.40 48.46 REMARK 500 GLN L 98 -114.23 -119.81 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 CA A 501 CA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 70 OD2 REMARK 620 2 ASN A 72 O 83.7 REMARK 620 3 GLN A 75 O 168.9 105.4 REMARK 620 4 GLU A 77 OE2 78.7 83.4 95.8 REMARK 620 5 GLU A 80 OE2 85.3 168.2 85.0 90.2 REMARK 620 6 HOH A 710 O 77.0 96.1 107.8 155.6 85.6 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CA A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE XLD A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 504 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1FJS RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO ZK807834 REMARK 900 RELATED ID: 1EZQ RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR128515 REMARK 900 RELATED ID: 1F0S RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR208707 REMARK 900 RELATED ID: 1F0R RELATED DB: PDB REMARK 900 FACTOR XA COMPLEXED TO RPR208815 REMARK 900 RELATED ID: 1QL7 RELATED DB: PDB REMARK 900 TRYSPIN COMPLEXED TO FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1QL9 RELATED DB: PDB REMARK 900 TRYSPIN COMPLEXED TO FACTOR XA INHIBITOR REMARK 900 RELATED ID: 1MQ5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL)AMINO] REMARK 900 CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- REMARK 900 THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA DBREF 1MQ6 A 16 243 UNP P00742 FA10_HUMAN 235 467 DBREF 1MQ6 L 87 137 UNP P00742 FA10_HUMAN 127 177 SEQRES 1 A 233 ILE VAL GLY GLY GLN GLU CYS LYS ASP GLY GLU CYS PRO SEQRES 2 A 233 TRP GLN ALA LEU LEU ILE ASN GLU GLU ASN GLU GLY PHE SEQRES 3 A 233 CYS GLY GLY THR ILE LEU SER GLU PHE TYR ILE LEU THR SEQRES 4 A 233 ALA ALA HIS CYS LEU TYR GLN ALA LYS ARG PHE LYS VAL SEQRES 5 A 233 ARG VAL GLY ASP ARG ASN THR GLU GLN GLU GLU GLY GLY SEQRES 6 A 233 GLU ALA VAL HIS GLU VAL GLU VAL VAL ILE LYS HIS ASN SEQRES 7 A 233 ARG PHE THR LYS GLU THR TYR ASP PHE ASP ILE ALA VAL SEQRES 8 A 233 LEU ARG LEU LYS THR PRO ILE THR PHE ARG MET ASN VAL SEQRES 9 A 233 ALA PRO ALA CYS LEU PRO GLU ARG ASP TRP ALA GLU SER SEQRES 10 A 233 THR LEU MET THR GLN LYS THR GLY ILE VAL SER GLY PHE SEQRES 11 A 233 GLY ARG THR HIS GLU LYS GLY ARG GLN SER THR ARG LEU SEQRES 12 A 233 LYS MET LEU GLU VAL PRO TYR VAL ASP ARG ASN SER CYS SEQRES 13 A 233 LYS LEU SER SER SER PHE ILE ILE THR GLN ASN MET PHE SEQRES 14 A 233 CYS ALA GLY TYR ASP THR LYS GLN GLU ASP ALA CYS GLN SEQRES 15 A 233 GLY ASP SER GLY GLY PRO HIS VAL THR ARG PHE LYS ASP SEQRES 16 A 233 THR TYR PHE VAL THR GLY ILE VAL SER TRP GLY GLU GLY SEQRES 17 A 233 CYS ALA ARG LYS GLY LYS TYR GLY ILE TYR THR LYS VAL SEQRES 18 A 233 THR ALA PHE LEU LYS TRP ILE ASP ARG SER MET LYS SEQRES 1 L 51 LYS LEU CYS SER LEU ASP ASN GLY ASP CYS ASP GLN PHE SEQRES 2 L 51 CYS HIS GLU GLU GLN ASN SER VAL VAL CYS SER CYS ALA SEQRES 3 L 51 ARG GLY TYR THR LEU ALA ASP ASN GLY LYS ALA CYS ILE SEQRES 4 L 51 PRO THR GLY PRO TYR PRO CYS GLY LYS GLN THR LEU HET CA A 501 1 HET XLD A 500 36 HET GOL A 502 6 HET GOL A 503 6 HET GOL A 504 6 HETNAM CA CALCIUM ION HETNAM XLD 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) HETNAM 2 XLD AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- HETNAM 3 XLD OXAZOLYL)METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 CA CA 2+ FORMUL 4 XLD C23 H20 CL3 N5 O4 S FORMUL 5 GOL 3(C3 H8 O3) FORMUL 8 HOH *164(H2 O) HELIX 1 1 ALA A 55 GLN A 61 5 7 HELIX 2 2 GLU A 124A THR A 131 1 8 HELIX 3 3 LEU A 131A GLN A 133 5 4 HELIX 4 4 ASP A 164 SER A 172 1 9 HELIX 5 5 PHE A 234 MET A 242 1 9 HELIX 6 6 LYS L 87 CYS L 96 5 10 SHEET 1 A 7 GLN A 20 GLU A 21 0 SHEET 2 A 7 LYS A 156 PRO A 161 -1 O MET A 157 N GLN A 20 SHEET 3 A 7 THR A 135 GLY A 140 -1 N GLY A 136 O VAL A 160 SHEET 4 A 7 PRO A 198 PHE A 203 -1 O VAL A 200 N ILE A 137 SHEET 5 A 7 THR A 206 TRP A 215 -1 O THR A 206 N PHE A 203 SHEET 6 A 7 GLY A 226 LYS A 230 -1 O ILE A 227 N TRP A 215 SHEET 7 A 7 MET A 180 ALA A 183 -1 N PHE A 181 O TYR A 228 SHEET 1 B 7 GLN A 30 ASN A 35 0 SHEET 2 B 7 GLY A 40 ILE A 46 -1 O PHE A 41 N LEU A 33 SHEET 3 B 7 TYR A 51 THR A 54 -1 O LEU A 53 N THR A 45 SHEET 4 B 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 B 7 ALA A 81 LYS A 90 -1 N ILE A 89 O VAL A 105 SHEET 6 B 7 PHE A 64 VAL A 68 -1 N VAL A 66 O HIS A 83 SHEET 7 B 7 GLN A 30 ASN A 35 -1 N LEU A 32 O ARG A 67 SHEET 1 C 2 PHE L 99 GLU L 102 0 SHEET 2 C 2 VAL L 107 SER L 110 -1 O VAL L 108 N HIS L 101 SHEET 1 D 2 TYR L 115 LEU L 117 0 SHEET 2 D 2 CYS L 124 PRO L 126 -1 O ILE L 125 N THR L 116 SSBOND 1 CYS A 22 CYS A 27 1555 1555 2.04 SSBOND 2 CYS A 42 CYS A 58 1555 1555 2.05 SSBOND 3 CYS A 122 CYS L 132 1555 1555 2.06 SSBOND 4 CYS A 168 CYS A 182 1555 1555 2.01 SSBOND 5 CYS A 191 CYS A 220 1555 1555 2.02 SSBOND 6 CYS L 89 CYS L 100 1555 1555 2.06 SSBOND 7 CYS L 96 CYS L 109 1555 1555 2.01 SSBOND 8 CYS L 111 CYS L 124 1555 1555 2.04 LINK OD2 ASP A 70 CA CA A 501 1555 1555 2.40 LINK O ASN A 72 CA CA A 501 1555 1555 2.10 LINK O GLN A 75 CA CA A 501 1555 1555 1.99 LINK OE2 GLU A 77 CA CA A 501 1555 1555 2.10 LINK OE2 GLU A 80 CA CA A 501 1555 1555 2.09 LINK CA CA A 501 O HOH A 710 1555 1555 1.81 SITE 1 AC1 6 ASP A 70 ASN A 72 GLN A 75 GLU A 77 SITE 2 AC1 6 GLU A 80 HOH A 710 SITE 1 AC2 17 LYS A 96 GLU A 97 TYR A 99 GLU A 146 SITE 2 AC2 17 PHE A 174 ASP A 189 ALA A 190 GLN A 192 SITE 3 AC2 17 VAL A 213 TRP A 215 GLY A 216 GLU A 217 SITE 4 AC2 17 GLY A 218 CYS A 220 GLY A 226 TYR A 228 SITE 5 AC2 17 HOH A 736 SITE 1 AC3 7 LEU A 47 SER A 48 GLU A 49 PHE A 114 SITE 2 AC3 7 PRO A 120 HOH A 702 TYR L 130 SITE 1 AC4 4 LEU A 123 PRO A 124 LEU A 235 HOH A 672 SITE 1 AC5 3 GLU A 84 SER A 130 CYS L 100 CRYST1 56.640 73.290 79.020 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017655 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013644 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012655 0.00000 CONECT 47 83 CONECT 83 47 CONECT 206 324 CONECT 324 206 CONECT 435 2223 CONECT 450 2223 CONECT 474 2223 CONECT 497 2223 CONECT 514 2223 CONECT 856 2184 CONECT 1240 1351 CONECT 1351 1240 CONECT 1433 1644 CONECT 1644 1433 CONECT 1869 1951 CONECT 1917 2022 CONECT 1951 1869 CONECT 2022 1917 CONECT 2034 2126 CONECT 2126 2034 CONECT 2184 856 CONECT 2223 435 450 474 497 CONECT 2223 514 2371 CONECT 2224 2225 2230 2231 CONECT 2225 2224 2226 CONECT 2226 2225 2227 CONECT 2227 2226 2228 2229 CONECT 2228 2227 CONECT 2229 2227 2230 CONECT 2230 2224 2229 CONECT 2231 2224 2232 CONECT 2232 2231 2233 2234 CONECT 2233 2232 CONECT 2234 2232 2235 2240 CONECT 2235 2234 2236 2243 CONECT 2236 2235 2237 2241 CONECT 2237 2236 2238 CONECT 2238 2237 2239 2240 CONECT 2239 2238 CONECT 2240 2234 2238 CONECT 2241 2236 2242 CONECT 2242 2241 CONECT 2243 2235 2244 CONECT 2244 2243 2245 2246 CONECT 2245 2244 CONECT 2246 2244 2247 2250 CONECT 2247 2246 2248 CONECT 2248 2247 2249 CONECT 2249 2248 2250 2252 CONECT 2250 2246 2249 2251 CONECT 2251 2250 CONECT 2252 2249 2253 CONECT 2253 2252 2254 2255 CONECT 2254 2253 CONECT 2255 2253 2256 2259 CONECT 2256 2255 2257 CONECT 2257 2256 2258 CONECT 2258 2257 2259 CONECT 2259 2255 2258 CONECT 2260 2261 2262 CONECT 2261 2260 CONECT 2262 2260 2263 2264 CONECT 2263 2262 CONECT 2264 2262 2265 CONECT 2265 2264 CONECT 2266 2267 2268 CONECT 2267 2266 CONECT 2268 2266 2269 2270 CONECT 2269 2268 CONECT 2270 2268 2271 CONECT 2271 2270 CONECT 2272 2273 2274 CONECT 2273 2272 CONECT 2274 2272 2275 2276 CONECT 2275 2274 CONECT 2276 2274 2277 CONECT 2277 2276 CONECT 2371 2223 MASTER 353 0 5 6 18 0 11 6 2439 2 78 22 END